![1]()
News
FDA advisors vote to recommend Moderna boosters
October 14, 2021
The panel voted to authorize a 50 milligram dose — half the dose used in the primary series of shots — to boost immunity against COVID-19 at least 6 month after the second dose.
News
CDC: Children just as vulnerable to COVID as adults
October 14, 2021
There were 113 COVID-19 outbreaks in schools without mask requirements, in a study of 1,000 schools in Arizona.
News
CDC chief overrules panel, OKs boosters for health care workers
September 24, 2021
Panelists “did not buy the need in occupational or institutional settings.”
![1]()
News
FDA OKs Pfizer COVID booster for 65 and over, those at high risk
September 23, 2021
Emerging evidence shows that booster doses of the Pfizer vaccine cause front-line immune defenders — called binding antibodies — to roughly triple soon after a person gets the third shot.
News
FDA panel backs Pfizer’s COVID booster for 65 and older, those at high risk
September 17, 2021
This followed an earlier 16-2 vote by the panel rejecting a booster dose for Americans age 16 and over.
![1]()
News
New Moderna vaccine data ‘support’ booster shot after 8 months
September 16, 2021
There is still a lot of debate in the medical community about the need for boosters.
News
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
![1]()
News
Heparin’s COVID-19 benefit greatest in moderately ill patients
August 13, 2021
A multiplatform trial reported that therapeutic heparin improved outcomes in moderately ill COVID-19 patients but not in critically ill patients.
![1]()
News
FDA authorizes booster shot for immunocompromised Americans
August 13, 2021
Those eligible for a third dose include solid organ transplant recipients, those undergoing cancer treatments, and people with autoimmune diseases that suppress their immune systems.
![1]()
News
FDA may okay COVID booster for vulnerable adults before weekend: Media
August 12, 2021
Between one-third and one-half of immunocompromised patients who didn’t develop detectable levels of virus-fighting antibodies after two doses of a COVID vaccine will respond to a third dose.
